Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients-Reference-Cited by-同舟云学术

Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients

Published:2022-12-16 Issue: Volume: Page:
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Fang Bangwei,Wei Yu,Zeng Hao,Li Yonghong,Chen Shouzhen,Zhang Tingwei,Pan Jian,Wang Beihe,Wu Junlong,Jin Shengming,Gan Hualei,Hu Mengna,Zhang Ding,Ye Dingwei,Zhu Yao

Funder

Shanghai Medical Innovation Research Special Project

General Program of Beijing Xisike Clinical Oncology Research Foundation

National Nature Science Foundation of China

Shanghai Shenkang Research Physician Innovation and Transformation Ability Training Project

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-022-03347-6.pdf

Reference49 articles.

1. Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56–61. https://doi.org/10.1126/science.aaa8172

2. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. https://doi.org/10.1056/NEJMoa1200690

3. Kwon ED, Drake CG, Scher HI et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:700–712. https://doi.org/10.1016/S1470-2045(14)70189-5

4. Beer TM, Kwon ED, Drake CG et al (2017) Randomized, Double-blind, phase iii trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35:40–47. https://doi.org/10.1200/JCO.2016.69.1584

5. Antonarakis ES, Piulats JM, Gross-Goupil M et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 38:395–405. https://doi.org/10.1200/JCO.19.01638

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer;Prostate Cancer and Prostatic Diseases;2024-04-02

2. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer;Journal of Translational Medicine;2024-01-14

3. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?;Critical Reviews in Clinical Laboratory Sciences;2023-10-26

4. Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity;Molecular Oncology;2023-08-23

5. Integrating Single-cell and Bulk RNA Sequencing Data Unveils Antigen Presentation and Process-related CAFs and Establishes a Predictive Signature in Prostate Cancer;2023-08-10